Chinese medicine compound for the convalescent COVID-19 patients: A multicenter, randomized, double-blind, placebo-controlled clinical trial protocol DOI Creative Commons
Rui Fang, Wookyeom Yang, Yue Zhou

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Дек. 2, 2024

Abstract Background Convalescent coronavirus disease 2019 (COVID-19) refers to a series of clinical syndromes in patients with COVID-19 infection that follow the relevant discharge indications but do not fulfill criteria for cure, and these are discharged from hospital residual multifunctional deficits, including coughing, fatigue, insomnia. The World Health Organization's preliminary statistics revealed over 65 million individuals worldwide experience 'long COVID', incidence rate each country varied 34–77%. Due prolonged convalescent infection, continue symptoms or develop new after three months some persist two without any apparent triggers, which has significant impact on health status quality life population. Patients lack definitive pharmacological treatment. Traditional Chinese medicine (TCM) exhibits distinct, synergistic effect treatment COVID-19. However, there exists limited number trials TCM lower evidence levels COVID-19; therefore, randomized urgently required. Methods A multicenter, randomized, double-blind, placebo-controlled, phase II trial was performed evaluate efficacy safety Shenlingkangfu (SLKF) granules treating lung-spleen qi deficiency syndrome. conducted through ten hospitals China's Hunan province, subjects recruited outpatient medical record platforms, inpatient case systems, subject recruitment advertisements. Eligible participants were aged 18–75 years, had confirmed physician-suspected severe acute respiratory syndrome 2 at least six prior, satisfied criteria. Individuals history pulmonary dysfunction major liver kidney illness those medications excluded. After 2-day adjustment period, all randomly divided into an intervention group (n = 77) control 77). given SLKF orally once bag, 16.9 g, twice daily, whereas received granule simulation same dosage. 14 days, assessments baseline days. primary outcomes therapeutic total symptom score. secondary included fatigue self-assessment scale, pain visual analog Pittsburgh sleep index, mini-mental state examination, anxiety depression score, C-reactive protein, erythrocyte sedimentation rate, interleukin-6. Three routine examinations, function tests, electrocardiography used as indicators. Discussion This study aimed verify whether can significantly improve symptoms, loss appetite, cough, phlegm, insomnia, For comprehensive investigation, additional larger sample sizes longer periods Trial registration Registered 26 January 2024, https://www.chictr.org.cn , identifier ChiCTR2400080348.

Язык: Английский

Organoids and Organ-On-Chip Models for COVID-19 Research and its Application in Modernization of Traditional Chinese Medicine: Opportunities and Challenges DOI Creative Commons

Hongda Sheng,

Yanchun Liang, Volker M. Lauschke

и другие.

Engineering, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Traditional Chinese Medicine Properties and Microcalorimetry: BioScience Evaluation DOI Creative Commons
Qiang Li, Hengrui Liu,

Jiayan Jin

и другие.

Опубликована: Апрель 18, 2025

ABSTRACT The properties theory of traditional Chinese medicine (TCM), characterized by cold, hot, warm, and cool four properties, is fundamental to its development, distinguishing it from natural, botanical, chemical medicines. However, despite significance, there no unified theoretical definition, bioscientific characterization, or standardized evaluation TCM's medicinal as scholars use diverse methods hold varying opinions. Historically, TCM practitioners relied on intuitive physical perspectives due limited scientific knowledge tools. This study aims investigate the nature core standards an underlying logical thinking physics perspective, with a focus ‘macro‐micro’ doctrine extension integration outlook. research examines current state, progress, trends in exploring their relationship ‘thermodynamic outlook properties' microcalorimetry. paper adopts systematic approach, drawing theories, methodologies, practical results various practitioners. Microcalorimetry employed method explore broader implications. highlights connection between thermodynamics, demonstrating effectiveness microcalorimetry understanding these properties. It presents structured “quality differentiation drug properties–drug are curative effect–curative effect monitoring clinical (‘Q’–P–‘C’)” introduces new concept “stylization TCM.” By integrating both shared characteristics individual differences methods, achievements multiple scholars, this provides feasible approach standardizing thereby further deepening application through structured, physics‐based framework.

Язык: Английский

Процитировано

0
Sanhan Huashi Formula and Its Bioactive Compounds Exert Antiviral and Anti-Inflammatory Effects on COVID-19 DOI Creative Commons
Chuanxi Tian, Hang Liu, Qian Wang

и другие.

Engineering, Год журнала: 2024, Номер unknown

Опубликована: Июль 1, 2024

Sanhan Huashi formula (SHHS), a traditional Chinese medicine (TCM), has shown significant therapeutic effects on coronavirus disease 2019 (COVID-19) in clinical settings. However, its specific mechanism and components still require further clarification. In vitro experiments with Vero-E6 cells infected severe acute respiratory syndrome 2 (SARS-CoV-2) demonstrated that SHHS effectively inhibited viral invasion proliferation. Complementary vivo using K18-human angiotensin converting enzyme (hACE2) mice exposed to virus-like particles (VLPs) confirmed impeded SARS-CoV-2 entry. Although did not demonstrate direct antiviral K18-hACE2 challenged SARS-CoV-2, it significantly alleviated pathological damage decreased the expression of chemokines such as C–C motif ligand (CCL)-2, CCL-3, C–X–C (CXCL)-1, CXCL-6, CXCL-9, CXCL-10, CXCL-11 lungs, suggesting exerts immunomodulatory anti-inflammatory via CCL-2–CXCL axis. Additional research lipopolysaccharide (LPS)-induced lung injury (ALI) RAW264.7 cell model validated ability reduce levels inflammatory biomarkers, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α). Using advanced analytical techniques ultrahigh-performance liquid chromatography coupled linear trap quadrupole Orbitrap mass spectrometry (UHPLC-LTQ-Orbitrap-MS) surface plasmon resonance (SPR), nodakenin was identified potent component targets 3C-like protease (3CLpro), finding supported by hydrogen–deuterium exchange (HDX-MS) molecular docking analyses. Furthermore, effect, reducing load more than 66%. This investigation reveals can combat COVID-19 inhibiting promoting effects.

Язык: Английский

Процитировано

1
Chinese medicine compound for the convalescent COVID-19 patients: A multicenter, randomized, double-blind, placebo-controlled clinical trial protocol DOI Creative Commons
Rui Fang, Wookyeom Yang, Yue Zhou

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Дек. 2, 2024

Abstract Background Convalescent coronavirus disease 2019 (COVID-19) refers to a series of clinical syndromes in patients with COVID-19 infection that follow the relevant discharge indications but do not fulfill criteria for cure, and these are discharged from hospital residual multifunctional deficits, including coughing, fatigue, insomnia. The World Health Organization's preliminary statistics revealed over 65 million individuals worldwide experience 'long COVID', incidence rate each country varied 34–77%. Due prolonged convalescent infection, continue symptoms or develop new after three months some persist two without any apparent triggers, which has significant impact on health status quality life population. Patients lack definitive pharmacological treatment. Traditional Chinese medicine (TCM) exhibits distinct, synergistic effect treatment COVID-19. However, there exists limited number trials TCM lower evidence levels COVID-19; therefore, randomized urgently required. Methods A multicenter, randomized, double-blind, placebo-controlled, phase II trial was performed evaluate efficacy safety Shenlingkangfu (SLKF) granules treating lung-spleen qi deficiency syndrome. conducted through ten hospitals China's Hunan province, subjects recruited outpatient medical record platforms, inpatient case systems, subject recruitment advertisements. Eligible participants were aged 18–75 years, had confirmed physician-suspected severe acute respiratory syndrome 2 at least six prior, satisfied criteria. Individuals history pulmonary dysfunction major liver kidney illness those medications excluded. After 2-day adjustment period, all randomly divided into an intervention group (n = 77) control 77). given SLKF orally once bag, 16.9 g, twice daily, whereas received granule simulation same dosage. 14 days, assessments baseline days. primary outcomes therapeutic total symptom score. secondary included fatigue self-assessment scale, pain visual analog Pittsburgh sleep index, mini-mental state examination, anxiety depression score, C-reactive protein, erythrocyte sedimentation rate, interleukin-6. Three routine examinations, function tests, electrocardiography used as indicators. Discussion This study aimed verify whether can significantly improve symptoms, loss appetite, cough, phlegm, insomnia, For comprehensive investigation, additional larger sample sizes longer periods Trial registration Registered 26 January 2024, https://www.chictr.org.cn , identifier ChiCTR2400080348.

Язык: Английский

Процитировано

0